Merck wins FDA conditional nod for Exzolt Cattle-CA1 therapy

Merck Animal Health, referred to as MSD Animal Health outside the U.S. and Canada, a branch of Merck & Co., Inc., Rahway, New Jersey, USA, revealed that the US Food and Drug Administration (FDA) has provided conditional approval for Exzolt Cattle-CA1 (fluralaner topical solution).

This cutting-edge product belongs to the latest category of parasiticides referred to as isoxazolines. The pour-on solution is successful in preventing and treating infestations from larvae of the New World screwworm (Cochliomyia hominivorax) (myiasis).

Also Read: Granules Consumer Health Clears USFDA Inspection with Zero Observation

It is additionally conditionally authorized for the management and regulation of cattle fever tick (Rhipicephalus microplus). “The danger posed by New World screwworm is an increasing worry for US agriculture, potentially leading to massive economic losses for cattle farmers that could amount to hundreds of millions of dollars,” stated Rick DeLuca, president of Merck Animal Health. “Exzolt Cattle-CA1 is the first new ectoparasiticide for beef cattle in many years, and its conditional approval demonstrates our dedication to delivering innovative solutions that tackle resistance issues.”

We collaborated with the FDA (Food and Drug Administration)  to hasten availability, ensuring that veterinarians and cattle producers can access an effective new tool to shield cattle from these severe parasites, thereby supporting the industry’s financial stability and the country’s beef supply. Exzolt Cattle-CA1 received conditional approval after proving safety and a reasonable expectation of effectiveness when used as directed, according to global studies conducted in recent years by Merck Animal Health